Impact of the CYP3A5 genotype on midazolam pharmacokinetics and pharmacodynamics during intensive care sedation

European Journal of Clinical Pharmacology

Volumn 63, Issue 12, 2007, Pages 1129-1133

  Fromm, Martin F ^a   Schwilden, Helmut ^b   Bachmakov, Iouri ^a   König, Jörg ^a   Bremer, Frank ^b   Schüttler, Jürgen ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

CYP3A5; Intensive care sedation; Midazolam; Pharmacogenetics; Polymorphism

Indexed keywords

CYTOCHROME P450 3A5; MIDAZOLAM;

ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CONFIDENCE INTERVAL; DRUG MONITORING; GENOTYPE; HUMAN; INFUSION RATE; INTENSIVE CARE; INTRACRANIAL TUMOR; MAJOR CLINICAL STUDY; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; RAMSAY SEDATION SCORE; SEDATION; TRAUMATIC BRAIN INJURY;

AGED; CONSCIOUS SEDATION; CYTOCHROME P-450 CYP3A; DRUG MONITORING; GENOTYPE; HUMANS; HYPNOTICS AND SEDATIVES; INTENSIVE CARE; MIDAZOLAM; MIDDLE AGED;

EID: 36149001659     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0365-6     Document Type: Article

References (25)

1. He P, Court MH, Greenblatt DJ, von Moltke LL (2005) Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Ther 77(5):373-387
2. Bremer F, Reulbach U, Schwilden H, Schuttler J (2004) Midazolam therapeutic drug monitoring in intensive care sedation: a 5-year survey. Ther Drug Monit 26(6):643-649
3. Xie, HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR (2004) Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5(3):243-272
4. Hustert, E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nüssler AC, Neuhaus P, Klattig J, Eiselt R, Koch I, Zibat A, Brockmöller J, Halpert JR, Zanger UM, Wojnowski L (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11(9):773-779
5. Kuehl, P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27(4):383-391
6. Dai, Y, Iwanaga K, Lin YS, Hebert MF, Davis CL, Huang W, Kharasch ED, Thummel KE (2004) In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochem Pharmacol 68(9):1889-1902
7. Kivistö, KT, Niemi M, Schaeffeler E, Pitkala K, Tilvis RT, Fromm MF, Schwab M, Eichelbaum M, Strandberg T (2004) Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 14(8):523-525
8. Mouly, SJ, Matheny C, Paine MF, Smith G, Lamba J, Lamba V, Pusek SN, Schuetz EG, Stewart PW, Watkins PB (2005) Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin Pharmacol Ther 78(6):605-618
9. Park, JY, Kim KA, Park PW, Lee OJ, Kang DK, Shon JH, Liu KH, Shin JG (2006) Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. Clin Pharmacol Ther 79(6):590-599
10. Eap, CB, Buclin T, Hustert E, Bleiber G, Golay KP, Aubert AC, Baumann P, Telenti A, Kerb R (2004) Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. Eur J Clin Pharmacol 60(4):231-236
11. Floyd, MD, Gervasini G, Masica AL, Mayo G, George AL Jr, Bhat K, Kim RB, Wilkinson GR (2003) Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 13(10):595-606
12. He, P, Court MH, Greenblatt DJ, von Moltke LL (2006) Factors influencing midazolam hydroxylation activity in human liver microsomes. Drug Metab Dispos 34(7):1198-1207
13. Huang, W, Lin YS, McConn DJ, Calamia JC, Totah RA, Isoherranen N, Glodowski M, Thummel KE (2004) Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos 32(12):1434-1445
14. Lepper, ER, Baker SD, Permenter M, Ries N, van Schaik RH, Schenk PW, Price DK, Ahn D, Smith NF, Cusatis G, Ingersoll RG, Bates SE, Mathijssen RH, Verweij J, Figg WD, Sparreboom A (2005) Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Clin Cancer Res 11(20):7398-7404
15. Shih, PS, Huang JD (2002) Pharmacokinetics of midazolam and 1′-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab Dispos 30(12):1491-1496
16. Williams JA, Cook J, Hurst SI (2003) A significant drug-metabolizing role for CYP3A5? Drug Metab Dispos 31(12):1526-1530
17. Wong M, Balleine RL, Collins M, Liddle C, Clarke CL, Gurney H (2004) CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clin Pharmacol Ther 75(6):529-538
18. Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumura K, Honda G, Nakagawa K, Ishizaki T, Kamataki T (2004) CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects. Drug Metab Pharmacokinet 19(2):120-129
19. Yu, KS, Cho JY, Jang IJ, Hong KS, Chung JY, Kim JR, Lim HS, Oh DS, Yi SY, Liu KH, Shin JG, Shin SG (2004) Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clin Pharmacol Ther 76(2):104-112
20. Fromm, MF, Schmidt BM, Pahl A, Jacobi J, Schmieder RE (2005) CYP3A5 genotype is associated with elevated blood pressure. Pharmacogenet Genomics 15(10):737-741
21. Albrecht, S, Ihmsen H, Hering W, Geisslinger G, Dingemanse J, Schwilden H, Schuttler J (1999) The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. Clin Pharmacol Ther 65(6):630-639
22. Jacobi, J, Fraser GL, Coursin DB, Riker RR, Fontaine D, Wittbrodt ET, Chalfin DB, Masica MF, Bjerke HS, Coplin WM, Crippen DW, Fuchs BD, Kelleher RM, Marik PE, Nasraway SA Jr, Murray MJ, Peruzzi WT, Lumb PD (2002) Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med 30(1):119-141
23. Odin I, Djebli N, Marquet P, Nathan N (2006) Midazolam metabolism and CYP 3A4 and 3A5: pharmacokinetics and pharmacogenetic interaction. Anesthesiology 105:A627, abstract
24. Park JY, Kim KA, Park PW, Lee OJ, Kang DK, Shon JH, Liu KH, Shin JG (2006) Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. Clin Pharmacol Ther 79(6):590-599
25. Foti RS, Fisher MB (2004) Importance of patient selection when determining the significance of the CYP3A5 polymorphism in clinical trials. Pharmacogenomics J 4(6):362-364